In last trading session, Legend Biotech Corp ADR (NASDAQ:LEGN) saw 1.26 million shares changing hands with its beta currently measuring 0.03. Company’s recent per share price level of $58.24 trading at -$1.79 or -2.98% at ring of the bell on the day assigns it a market valuation of $10.59B. That closing price of LEGN’s stock is at a discount of -32.76% from its 52-week high price of $77.32 and is indicating a premium of 25.57% from its 52-week low price of $43.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.51 million shares which gives us an average trading volume of 977.42K if we extend that period to 3-months.
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Upright in the red during last session for losing -2.98%, in the last five days LEGN remained trading in the red while hitting it’s week-highest on Friday, 03/15/24 when the stock touched $58.24 price level, adding 15.8% to its value on the day. Legend Biotech Corp ADR’s shares saw a change of -3.21% in year-to-date performance and have moved -11.90% in past 5-day. Legend Biotech Corp ADR (NASDAQ:LEGN) showed a performance of -2.66% in past 30-days. Number of shares sold short was 10.26 million shares which calculate 13.11 days to cover the short interests.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Statistics highlight that Legend Biotech Corp ADR is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -9.34% of value to its shares in past 6 months, showing an annual growth rate of 5.44% while that of industry is 12.10. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 52.90% in the current quarter and calculating 56.10% increase in the next quarter. This year revenue growth is estimated to rise 114.10% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $173.54 million for the same. And 9 analysts are in estimates of company making revenue of $145.75 million in the next quarter that will end on Jun 2024. Company posted $36.34 million and $73.33 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 377.60% while estimating it to be 98.80% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -168.48% during past 5 years.
LEGN Dividends
Legend Biotech Corp ADR is more likely to be releasing its next quarterly report between May 13 and May 18 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
Insiders are in possession of 1.29% of company’s total shares while institution are holding 48.69 percent of that, with stock having share float percentage of 49.32%. Investors also watch the number of corporate investors in a company very closely, which is 48.69% institutions for Legend Biotech Corp ADR that are currently holding shares of the company. FMR, LLC is the top institutional holder at LEGN for having 17.05 million shares of worth $1.18 billion. And as of Jun 29, 2023, it was holding 10.33% of the company’s outstanding shares.
The second largest institutional holder is Price (T.Rowe) Associates Inc, which was holding about 9.03 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 5.47% of outstanding shares, having a total worth of $623.43 million.
On the other hand, Smallcap World Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 3.15 million shares of worth $217.33 million or 1.91% of the total outstanding shares. The later fund manager was in possession of 1.76 million shares on Aug 30, 2023, making its stake of worth around $122.28 million in the company or a holder of 1.07% of company’s stock.
